"Pulse" biomedical and high performance medical devices
Release date: 2015-11-11 Recently, in order to identify the development trends and development priorities of the ten key areas and guide the innovation activities of enterprises, the National Manufacturing Power Construction Strategy Advisory Committee specially organized the technical roadmaps of these ten fields, which were compiled into a book called “China Manufacturing 2025 "Technical Roadmap for Key Areas". Since the cover is green, it can also be called “Green Paper for Technological Innovation in the Key Fields of Made in China 2025†(hereinafter referred to as the Green Paper). Biomedical and high-performance medical devices are among the top ten key areas. "Made in China 2025" proposes to develop new products for chemical drugs, traditional Chinese medicines and biotechnology drugs for major diseases, focusing on new mechanisms and new target chemical drugs, antibody drugs, antibody-conjugated drugs, new structural proteins and peptide drugs, and new vaccines. Innovative Chinese medicines and personalized therapeutic drugs with outstanding clinical advantages; improve the innovation ability and industrialization level of medical devices, focus on the development of high-performance Medical Equipment such as imaging equipment and medical robots, high-grade medical consumables such as fully degradable blood vessel stents, and wearable, Mobile medical products such as telemedicine. Breakthrough and application of new technologies such as biological 3D printing and induced pluripotent stem cells. The Green Paper proposes that the development goal of biomedicine is to promote a large number of enterprises to achieve drug quality standards and systems in line with international standards by 2020, at least 100 pharmaceutical preparation companies have obtained the United States, Europe, Japan and the World Health Organization (WHO). Certification and realization of product export; in accordance with international drug standards, develop and promote 10 to 20 chemical drugs and high-end preparations, 3 to 5 new Chinese medicines, 3 to 5 new biotechnology drugs to complete drug registration in developed countries such as Europe and the United States, Accelerate the international development of domestically produced drugs. More than 90% of the heavy drugs that expired international patents by 2020 will be copied. Break through 10 to 15 major core key technologies and initially establish a national drug innovation system and innovation team. In 2025, the basic standards for the implementation of pharmaceutical quality standards and systems are in line with international standards; the development of new products for chemical diseases, traditional Chinese medicines and biotechnology drugs for ten major diseases, achieving 20 to 30 innovative drug industrialization; 5 to 10 new drugs for independent property rights in China Through the US Food and Drug Administration (FDA) or EU certification, enter the international market; build a national drug innovation system that complements and supports external services, form a high-level innovation team with an international vision, and promote the development strategy of China's pharmaceutical internationalization. The development goal for medical devices is: the industrial development goal in 2020 is: the annual industrial scale reaches 600 billion yuan; the domestic high-end medical device market share of county-level hospitals reaches 50%; the domestic market share of domestic core components reaches 60%; More than 5 scientific and technological achievements engineering platform and collaborative innovation center; 20 demonstration application bases; 3 or more international famous brands. The industrial development goal in 2025 is: the annual industrial scale reaches 1.2 trillion yuan; the domestic high-end medical equipment market share of county-level hospitals reaches 70%; the domestic market share of domestic core components reaches 80%; and more than 10 scientific and technological achievements projects are built nationwide. The platform and the collaborative innovation center; the formation of six provincial-level industrial clusters with an output value exceeding 100 billion yuan; the formation of 30 demonstration application bases; and the formation of more than 5 internationally renowned brands in each major product field . Source: Chinese Journal of Science Anesthesia Medical Co., Ltd. , https://www.medicaldiverse.com